Pharmacy and Wellness Review
Abstract
Long coronavirus disease (COVID) is a condition that affects millions of individuals worldwide. Long COVID manifests as persistent symptoms following acute COVID-19. These symptoms can include, but are not limited to, fatigue, cognitive dysfunction, and chronic inflammation often lasting for months and significantly impairing patients' quality of life. As the number of Long COVID cases continues to rise and major global health organizations begin to standardize Long COVID’s mechanisms and diagnosis, there is an increasing demand for effective treatments that can address its complex nature. While some therapies, such as metformin and hyperbaric oxygen therapy (HBOT) have shown promise in symptom management, these treatments have limitations in terms of efficacy, accessibility, and cost. Bezisterim, an investigational anti-inflammatory drug, has recently gained Food and Drug Administration (FDA) authorization for a clinical trial to address the persistent symptoms of Long COVID. This milestone represents a significant advancement in the ongoing search for effective treatments for post-viral syndromes. Long COVID continues to pose challenges with millions of patients experiencing debilitating symptoms and limited therapeutic options. Bezisterim's ability to modulate chronic inflammation offers promising potential to alleviate these symptoms and improve patient outcomes. The results of these trials could have far-reaching implications and offer new hope for patients suffering from Long COVID and other chronic inflammatory diseases. This paper explores the drug's mechanism of action, the significance of the FDA’s trial authorization, and the ongoing research efforts to address unmet clinical needs.
Included in
COVID-19 Commons, Epidemiology Commons, Virus Diseases Commons